Preferences in Cyclin-Dependent Kinase 4/6 Inhibitors for Advanced Breast Cancer Among Medical Oncologists in Latin America

Although CDK4/6i are accepted as essential therapies for advanced BC, substantial institutional access barriers persist in Latin America. Clinical preferences reflect both emerging evidence and local constraints. Broader integration of CDK4/6i into public formularies and continuous generation of real-world data are critical for improving equity and outcomes in the region.